A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-platelet Therapy, in Patients Undergoing High-risk Coronary Angioplasty

NCT00269893 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

2038

Enrollment

INDUSTRY

Sponsor class

Conditions

Angina, Unstable
Angioplasty, Transluminal, Percutaneous Coronary

Interventions

DRUG: Abciximab
DRUG: Placebo

Sponsor

Centocor, Inc.